Clinical Trials Logo

Endometrial Mixed Adenocarcinoma clinical trials

View clinical trials related to Endometrial Mixed Adenocarcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT01737619 Active, not recruiting - Clinical trials for Endometrial Serous Adenocarcinoma

PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer

Start date: April 3, 2013
Phase: N/A
Study type: Interventional

This clinical trial studies positron emission tomography (PET)/computed tomography (CT) and lymph node mapping in finding lymph node metastasis in patients with endometrial cancer that is at high risk of spreading. A PET/CT scan is a procedure that combines the pictures from a PET scan and a CT scan, which are taken at the same time from the same machine. The combined scans give more detailed pictures of areas inside the body than either scan gives by itself. Lymph node mapping uses a radioactive dye, called indocyanine green solution, to identify lymph nodes that may contain cancer cells. PET/CT and sentinel lymph node mapping may be better ways than surgery to identify cancer in the lymph nodes.

NCT ID: NCT01642082 Completed - Clinical trials for Endometrial Adenocarcinoma

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

Start date: September 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well dalantercept works in treating patients with endometrial cancer that has come back or is persistent. Dalantercept may stop the growth of endometrial cancer by blocking blood flow to the tumor.

NCT ID: NCT00888173 Completed - Clinical trials for Endometrial Adenocarcinoma

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Start date: July 6, 2009
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well brivanib alaninate works in treating patients with endometrial cancer that has come back (recurred) or is persistent. Brivanib alaninate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00575952 Completed - Clinical trials for Endometrial Serous Adenocarcinoma

Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer

Start date: January 17, 2008
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of intraperitoneal paclitaxel when given together with doxorubicin hydrochloride and cisplatin in treating patients with stage III-IV endometrial cancer. Drugs used in chemotherapy, such as paclitaxel, doxorubicin hydrochloride, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them in different ways may kill more tumor cells.